Developing treatments for antibiotic
resistant bacterial infections
is among the highest priority public health challenges worldwide.
Tetracyclines, one of the most important classes of antibiotics, have
fallen prey to antibiotic resistance, necessitating the generation
of new analogs. Many tetracycline analogs have been accessed through
both total synthesis and semisynthesis, but key C-ring tetracycline
analogs remain inaccessible. New methods are needed to unlock access
to these analogs, and heterologous biosynthesis in a tractable host
such as Saccharomyces cerevisiae is a candidate method.
C-ring analog biosynthesis can mimic nature’s biosynthesis
of tetracyclines from anhydrotetracyclines, but challenges exist,
including the absence of the unique cofactor F420 in common
heterologous hosts. Toward this goal, this paper describes the biosynthesis
of tetracycline from anhydrotetracycline in S. cerevisiae heterologously expressing three enzymes from three bacterial hosts:
the anhydrotetracycline hydroxylase OxyS, the dehydrotetracycline
reductase CtcM, and the F420 reductase FNO. This biosynthesis
of tetracycline is enabled by OxyS performing just one hydroxylation
step in S. cerevisiae despite its previous characterization
as a double hydroxylase. This single hydroxylation enabled us to purify
and structurally characterize a hypothetical intermediate in oxytetracycline
biosynthesis that can explain structural differences between oxytetracycline
and chlortetracycline. We show that Fo, a synthetically
accessible derivative of cofactor F420, can replace F420 in tetracycline biosynthesis. Critically, the use of S. cerevisiae for the final steps of tetracycline biosynthesis
described herein sets the stage to achieve a total biosynthesis of
tetracycline as well as novel tetracycline analogs in S. cerevisiae with the potential to combat antibiotic-resistant bacteria.